Regeneron Pharmaceuticals Inc
REGN651.800USD
-2.240-0.34%
Close 10/31, 16:00（ET）Quotes delayed by 15 min
68.63BMarket Cap
14.99P/E TTM
More Details of Regeneron Pharmaceuticals Inc Company
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company helps in accelerating and improving the traditional drug development process through its VelociSuite technologies, such as VelocImmune, which uses genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center. Its marketed products include EYLEA (aflibercept) Injection; Dupixent (dupilumab) Injection; Libtayo (cemiplimab) Injection; Praluent (alirocumab) Injection; Kevzara (sarilumab) Injection, and others.
Regeneron Pharmaceuticals Inc Info
Ticker SymbolREGN
Company nameRegeneron Pharmaceuticals Inc
IPO dateApr 02, 1991
CEODr. Leonard S. Schleifer, M.D., Ph.D
Number of employees15106
Security typeOrdinary Share
Fiscal year-endApr 02
Address777 Old Saw Mill River Road
CityTARRYTOWN
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code10591
Phone17813705000
Websitehttps://www.regeneron.com/
Ticker SymbolREGN
IPO dateApr 02, 1991
CEODr. Leonard S. Schleifer, M.D., Ph.D
Company Executives of Regeneron Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Dr. George D. Yancopoulos, M.D., Ph.D
Dr. George D. Yancopoulos, M.D., Ph.D
Co-Chairman of the Board, President, Chief Scientific Officer
Co-Chairman of the Board, President, Chief Scientific Officer
1.11M
+42.02%
Dr. Leonard S. Schleifer, M.D., Ph.D
Dr. Leonard S. Schleifer, M.D., Ph.D
Co-Chairman of the Board, President, Chief Executive Officer, Founder
Co-Chairman of the Board, President, Chief Executive Officer, Founder
670.48K
-3.59%
Dr. Andrew J. Murphy, Ph.D.
Dr. Andrew J. Murphy, Ph.D.
Executive Vice President - Research
Executive Vice President - Research
54.39K
+1.82%
Mr. Joseph J. LaRosa
Mr. Joseph J. LaRosa
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
42.00K
+2.78%
Mr. Daniel P. Van Plew
Mr. Daniel P. Van Plew
Executive Vice President, General Manager - Industrial Operations and Product Supply
Executive Vice President, General Manager - Industrial Operations and Product Supply
35.92K
+0.07%
Mr. George L. Sing
Mr. George L. Sing
Independent Director
Independent Director
29.89K
-0.06%
Mr. Christopher R. Fenimore
Mr. Christopher R. Fenimore
Chief Financial Officer, Executive Vice President - Finance
Chief Financial Officer, Executive Vice President - Finance
19.75K
+20.78%
Mr. Arthur F. (Art) Ryan
Mr. Arthur F. (Art) Ryan
Independent Director
Independent Director
17.66K
-0.10%
Ms. Marion E. McCourt
Ms. Marion E. McCourt
Executive Vice President - Commercial
Executive Vice President - Commercial
14.37K
+9.94%
Dr. Michael S. Brown, M.D.
Dr. Michael S. Brown, M.D.
Independent Director
Independent Director
12.62K
-0.13%
View more
Name
Name/Position
Position
Shareholding
Change
Dr. George D. Yancopoulos, M.D., Ph.D
Dr. George D. Yancopoulos, M.D., Ph.D
Co-Chairman of the Board, President, Chief Scientific Officer
Co-Chairman of the Board, President, Chief Scientific Officer
1.11M
+42.02%
Dr. Leonard S. Schleifer, M.D., Ph.D
Dr. Leonard S. Schleifer, M.D., Ph.D
Co-Chairman of the Board, President, Chief Executive Officer, Founder
Co-Chairman of the Board, President, Chief Executive Officer, Founder
670.48K
-3.59%
Dr. Andrew J. Murphy, Ph.D.
Dr. Andrew J. Murphy, Ph.D.
Executive Vice President - Research
Executive Vice President - Research
54.39K
+1.82%
Mr. Joseph J. LaRosa
Mr. Joseph J. LaRosa
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
42.00K
+2.78%
Mr. Daniel P. Van Plew
Mr. Daniel P. Van Plew
Executive Vice President, General Manager - Industrial Operations and Product Supply
Executive Vice President, General Manager - Industrial Operations and Product Supply
35.92K
+0.07%
Mr. George L. Sing
Mr. George L. Sing
Independent Director
Independent Director
29.89K
-0.06%
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Sanofi
1.44B
39.28%
EYLEA
754.30M
20.52%
Bayer
415.00M
11.29%
EYLEA HD
393.20M
10.70%
Libtayo
247.80M
6.74%
Other
421.70M
11.47%
No Data
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Sanofi
1.44B
39.28%
EYLEA
754.30M
20.52%
Bayer
415.00M
11.29%
EYLEA HD
393.20M
10.70%
Libtayo
247.80M
6.74%
Other
421.70M
11.47%
Shareholding Stats
Updated: Sat, Aug 30
Updated: Sat, Aug 30
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
9.07%
BlackRock Institutional Trust Company, N.A.
5.49%
State Street Investment Management (US)
4.68%
Dodge & Cox
3.70%
Fidelity Management & Research Company LLC
3.16%
Other
73.90%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
9.07%
BlackRock Institutional Trust Company, N.A.
5.49%
State Street Investment Management (US)
4.68%
Dodge & Cox
3.70%
Fidelity Management & Research Company LLC
3.16%
Other
73.90%
Shareholder Types
Shareholders
Proportion
Investment Advisor
48.18%
Investment Advisor/Hedge Fund
28.87%
Hedge Fund
5.39%
Research Firm
2.72%
Pension Fund
2.56%
Bank and Trust
2.16%
Individual Investor
2.02%
Sovereign Wealth Fund
1.23%
Insurance Company
0.08%
Other
6.77%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
2594
94.25M
91.26%
-4.09M
2025Q2
2585
99.72M
95.69%
-2.03M
2025Q1
2621
99.84M
93.97%
-1.42M
2024Q4
2581
100.17M
93.15%
-475.65K
2024Q3
2505
99.81M
90.67%
-1.99M
2024Q2
2479
100.87M
93.10%
+570.24K
2024Q1
2440
99.77M
92.44%
+388.23K
2023Q4
2406
98.50M
91.94%
-617.06K
2023Q3
2358
98.79M
92.52%
-1.71M
2023Q2
2360
99.25M
92.00%
-1.42M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
9.37M
9%
+14.55K
+0.16%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
5.67M
5.44%
-75.61K
-1.32%
Jun 30, 2025
State Street Investment Management (US)
4.83M
4.64%
+42.34K
+0.88%
Jun 30, 2025
Dodge & Cox
3.83M
3.67%
+1.50M
+64.64%
Jun 30, 2025
Fidelity Management & Research Company LLC
3.26M
3.13%
-4.14M
-55.90%
Jun 30, 2025
Capital International Investors
3.17M
3.04%
-823.87K
-20.65%
Jun 30, 2025
JP Morgan Asset Management
2.82M
2.7%
-1.26M
-30.95%
Jun 30, 2025
Geode Capital Management, L.L.C.
2.47M
2.37%
-4.53K
-0.18%
Jun 30, 2025
Invesco Capital Management (QQQ Trust)
2.17M
2.09%
-7.70K
-0.35%
Aug 31, 2025
Putnam Investment Management, L.L.C.
2.03M
1.95%
+116.30K
+6.08%
Jun 30, 2025
View more
Related ETFs
Updated: 6 hours ago
Updated: 6 hours ago
Name
Proportion
iShares Biotechnology ETF
5.44%
Amplify Weight Loss Drug & Treatment ETF
4.78%
JPMorgan Healthcare Leaders ETF
2.31%
SPDR S&P Biotech ETF
2.09%
Putnam Focused Large Cap Value ETF
1.57%
Pacer US Cash Cows 100 ETF
1.16%
Health Care Select Sector SPDR Fund
1.14%
JPMorgan Equity Premium Income ETF
0.8%
Pacer CFRA-Stovall Equal Weight Seasonal Rot Idx
0.76%
Indexperts Quality Earnings Focused ETF
0.66%
View more
iShares Biotechnology ETF
Proportion5.44%
Amplify Weight Loss Drug & Treatment ETF
Proportion4.78%
JPMorgan Healthcare Leaders ETF
Proportion2.31%
SPDR S&P Biotech ETF
Proportion2.09%
Putnam Focused Large Cap Value ETF
Proportion1.57%
Pacer US Cash Cows 100 ETF
Proportion1.16%
Health Care Select Sector SPDR Fund
Proportion1.14%
JPMorgan Equity Premium Income ETF
Proportion0.8%
Pacer CFRA-Stovall Equal Weight Seasonal Rot Idx
Proportion0.76%
Indexperts Quality Earnings Focused ETF
Proportion0.66%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
Feb 04, 2025
REGN.NB Interim Cash Dividend of gross USD 0.88 paid on Mar 20, 2025 going ex on Feb 20, 2025
Feb 20, 2025
Mar 20, 2025
Feb 20, 2025
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
